Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semaglutide controlled release - Mapi Pharma

Next Previous
X
Search
Drug Profile

Semaglutide controlled release - Mapi Pharma

Alternative Names: GLP-1 - Mapi Pharma; GLP-1 Depot; Semaglutide - Mapi Pharma

Latest Information Update: 03 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mapi Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetes mellitus

Most Recent Events

  • 19 Oct 2022 Phase-II clinical trials in Diabetes mellitus in Israel (Parenteral) (Mapi Pharma pipeline, October 2022)
  • 11 Nov 2021 Glucagon-like peptide controlled release - Mapi Pharma is available for licensing as of 11 Nov 2021. https://mapi-pharma.com/about/our-strategy/
  • 10 Nov 2021 Early research in Diabetes mellitus in Israel (unspecified route) (Mapi Pharma pipeline, November 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top